You just read:

New Long-Term Data Demonstrates Continued Safety and Beneficial Effect of Ofev® (Nintedanib) for Patients with IPF

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Sep 07, 2016, 08:00 ET